Format

Send to

Choose Destination
Int Immunopharmacol. 2017 Nov;52:197-202. doi: 10.1016/j.intimp.2017.09.014. Epub 2017 Sep 21.

Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC.

Author information

1
Department of Oncology, The Affiliated Central Hospital of Qingdao University, 127 Siliu South Road, Qingdao 266042, China.
2
Department of Clinical Laboratory, The Affiliated Central Hospital of Qingdao University, 127 Siliu South Road, Qingdao 266042, China.
3
Biotherapy Center, The Affiliated Central Hospital of Qingdao University, 127 Siliu South Road, Qingdao 266042, China. Electronic address: sunweihong@126.com.
4
Biotherapy Center, The Affiliated Central Hospital of Qingdao University, 127 Siliu South Road, Qingdao 266042, China.
5
Department of Oncology, The Affiliated Central Hospital of Qingdao University, 127 Siliu South Road, Qingdao 266042, China. Electronic address: maxuezhen1968@126.com.

Abstract

Regulatory T cells (Tregs) suppress antitumor immune responses. Cycles of Dendritic cells (DC) vaccination combined with cytokine-induced killer (CIK) cells (DC/CIK) treatment were significantly related with good prognosis. Therefore, we investigated whether increased cycles of immunotherapy could decrease frequency of Tregs in patients with resected non-small cell lung cancer (NSCLC). Previous study from our laboratory has determined that the optimal cutoff point of the cycle count was 3cycles. We examined the levels of Tregs and the related cytokines by flow cytometric and cytokine analysis in these patients after more than (≥) 3cycles or less than (<) 3cycles of DC/CIK cell treatment. Significant reduction of Tregs frequency, Treg-generated cytokines level and recurrence rate were presented in patients received with ≥3cycles of DC/CIK cell treatment compared with patients with <3cycles of treatment. Interestingly, Tregs frequency and the related cytokines level were similar between patients suffered tumor recurrence and patients without recurrence in both groups. Together, our findings reveal that increased cycle count of DC/CIK cell immunotherapy contribute to decline of Tregs frequency and cancer recurrence rate in patients with resected NSCLC.

KEYWORDS:

Cytokine-induced killer cell; Dendritic cell; Foxp3(+) Treg cells; Immunotherapy; Non-small cell lung cancer

PMID:
28941416
DOI:
10.1016/j.intimp.2017.09.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center